HKEX reiterates plans to expand listing eligibility for biotechs

Hong Kong Exchanges and Clearing Ltd. (HKEX) published Friday the second round of its consultation paper proposing to amend listing rules to allow pre-revenue biotechs and companies from emerging and innovative sectors with weighted voting rights (WVR) structures to list on the Hong Kong Stock Exchange’s main board.

The updated paper, which incorporated input from the Securities and Futures Commission and stakeholders, is in line with the initial version of the document released in December (see BioCentury Extra, Dec. 15, 2017)...